CARDIOSTER
ActiveSummary
CARDIOSTER has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €583,286 and a net result of €257,753. Equity is growing by about 11% per year across the filed financial years. Its solvency ranks better than 79% of 9,506 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-06
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2018 to 2025net €257,753 ▲11.5%
Operating result €359,957, net result €257,753, both a record.
31-12
Financial
Equity above €500,000equity €583,286 ▲37.1%
A profit in every financial year since 2018 builds equity to €583,286.
06-06
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
29-05
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Equity above €200,000equity €294,389 ▲51.9%
A profit in every financial year since 2018 builds equity to €294,389.
01-07
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
15-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
06-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
01-07
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
22-07
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
02-08
NBB filing
Annual accounts filed
financial year 2017 · micro format · 2 days late
2017
01-08
NBB filing
Annual accounts filed
financial year 2016 · micro format · 1 day late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 17 annual accounts filed, the latest 10 are here; all 17 are under Financials.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.